Albendazole-Ivermectin Premix Veterinary Grade API is a fixed-ratio active pharmaceutical ingredient mixture intended for downstream formulation into tablets, injections, capsules, powders, granules, feed premixes, and non-aqueous solutions. The model designation ABZ-IVM-PMX-100/2.5 identifies a carrier-dispersed system containing albendazole at 100 mg/g and ivermectin at 2.5 mg/g on a low-moisture lactose monohydrate carrier, with residual moisture controlled to not more than 4.0% w/w after vacuum drying at 60 °C. Albendazole, CAS 54965-21-8, is a benzimidazole carbamate with a molecular weight of 265.33 g/mol; ivermectin, CAS 70288-86-7, is a semisynthetic macrocyclic lactone composed primarily of ivermectin B1a with a molecular weight of 875.10 g/mol and ivermectin B1b with a molecular weight of 861.10 g/mol, with B1a present at not less than 80% and B1b present at not more than 20% under pharmacopoeial limits. The premix is manufactured through sequential geometric dilution in a 600 L double-cone blender followed by cone milling through a 0.8 mm round-hole screen, producing a D90 particle size of 180 µm to 250 µm as measured by laser diffraction under ISO 13320-1:2020. This particle size range balances blend uniformity against dusting losses observed when the fraction below 45 µm exceeds 25% w/w. The product differs from simple co-milling of separate albendazole and ivermectin powders because the carrier deposition step fixes the low-dose ivermectin to the lactose surface, reducing segregation during pneumatic transfer and long hopper hold times in production-scale tablet presses.

What Limits Direct Compression of the Fixed-Ratio Premix in Tablet Manufacturing?

Albendazole crystals exhibit brittle fracture and high elastic recovery, so direct compression of the undiluted premix without wet granulation typically produces tablets with friability above 1.0% and capping at compaction pressures above 120 MPa. In production trials on a 16-station rotary press with 8 mm standard concave tooling, tablet formulations containing 35% w/w premix, 48% w/w microcrystalline cellulose PH102, 12% w/w croscarmellose sodium, 3% w/w povidone K30 binder, and 0.5% w/w magnesium stearate were prepared by low-shear wet granulation using an aqueous binder solution at 18% w/w solids. Granule drying in a fluid-bed dryer to a final moisture of 2.0% w/w to 2.8% w/w yielded tablet hardness of 7 kp to 10 kp and friability of 0.3% to 0.6%, tested according to USP <1216>. Wet granulation is preferred because the presence of both actives on the same carrier particle minimizes assay segregation after drying; however, granulation fluid temperature must remain below 40 °C to avoid ivermectin degradation on the lactose surface. Sticking to punch faces is observed when the premix contains more than 10% w/w fines below 45 µm, so pre-screening through a 0.5 mm sieve is required before charging the granulator.

For injectable dosage forms, the high lipid solubility of ivermectin and the very low aqueous solubility of albendazole necessitate non-aqueous vehicles or co-solvent systems. A typical sterile injectable preparation combines the premix with glycerol formal at 30% v/v, propylene glycol at 60% v/v, and benzyl alcohol at 2% v/v, with active concentrations adjusted to deliver 10 mg/kg albendazole and 0.25 mg/kg ivermectin in ruminant protocols. Terminal sterilization by moist heat is not applicable to aqueous formulations above pH 7.0 because albendazole converts to albendazole sulfoxide under alkaline oxidative conditions; therefore, aseptic filtration through 0.22 µm polyvinylidene fluoride membranes is used after cold dissolution at 8 °C to 12 °C. Production-scale filling lines require continuous nitrogen blanketing because ivermectin is sensitive to oxygen and ultraviolet light, with a color shift from pale yellow to amber indicating oxidative degradation products exceeding 2.0% total impurities by HPLC area normalization. Injectable formulations should be filtered within 2 hours of vehicle mixing because precipitation of albendazole from chilled co-solvent systems proceeds rapidly when solution temperature rises above 15 °C.

Premix and Powder Feed Application: Segregation Risk at 2.5 mg/g Ivermectin Load

Production of feed premixes containing albendazole at 100 mg/g and ivermectin at 2.5 mg/g requires strict attention to blend uniformity in a horizontal ribbon blender with a 60% fill volume and a rotor tip speed of 1.2 m/s to 1.8 m/s. The low ivermectin proportion means that a 1.0% bulk loss during transfer can shift the effective dose by up to 12% in the final medicated feed if the premix is not carrier-anchored. Sampling with a grain thief at 10 locations after 15 minutes of blending yields a relative standard deviation below 3.0% for both actives when the carrier particle size distribution is between 150 µm and 500 µm. If the blend is discharged through a bin vent filter with an extraction velocity above 1.0 m/s, electrostatic losses of the fine ivermectin fraction can raise assay variability to 8% RSD in field samples; grounding and humidification to 45% RH to 60% RH are necessary control measures. This product differs from uncoated physical mixtures because the ivermectin is deposited onto the surface of the lactose carrier during manufacture, producing a single-particle population rather than two discrete particle populations with different bulk densities. Published data for this specific fixed-ratio carrier system in large-volume feed mills is limited, so manufacturers should confirm blend uniformity through process validation under actual production humidity and transfer conditions.

Capsule and granule operations require a densification step because the premix as supplied has a bulk density of 0.42 g/mL to 0.48 g/mL, which is insufficient for size 00 capsule filling when target fill weight exceeds 450 mg. Dry granulation by slugging on a 20 mm flat-faced tool at 8 kN to 12 kN compaction force increases bulk density to 0.58 g/mL to 0.62 g/mL and reduces the tamping pin pressure required on an automatic capsule machine to less than 6 N. The granulation process does not require binder addition when premix moisture content is above 2.5% w/w; below that threshold, 2.0% w/w sorbitol solution is sprayed into the slugged material to reduce fines and maintain granule hardness of 3 N to 5 N as measured by a texture analyzer. Granule flow through a 10 mm orifice is typically 4 g/s to 6 g/s after slugging, meeting the flow requirements for high-speed capsule filling equipment. Encapsulated products should be packaged in aluminum foil blisters with desiccant because the lactose carrier begins to cake at storage relative humidity above 60% RH.

When Aqueous Oral Solutions Require pH Adjustment Beyond Albendazole’s Solubility Window

Albendazole exhibits pH-dependent solubility with an intrinsic dissolution rate below 0.5 µg/min/cm² in phosphate buffer at pH 6.8, and ivermectin is practically insoluble in water; therefore, true aqueous oral solutions are not an appropriate application for this premix without high-concentration co-solvents. A non-aqueous oral drench may be prepared with propylene glycol caprylate and ethanol, but the flash point falls below 21 °C, requiring explosion-proof mixing equipment and transfer pumps. Suspensions are preferred for aqueous administration: the premix is dispersed in 0.5% w/w sodium carboxymethylcellulose with 0.2% w/w polysorbate 80 and 0.1% w/w sodium benzoate, then homogenized through a rotor-stator high-shear mixer at 10,000 rpm for 10 minutes. The resulting suspension achieves a D90 of 30 µm and remains resuspendable after storage at 25 °C for 14 days, with sedimentation volume above 0.85. Manufacturers should avoid high-pH buffering agents because albendazole degradation accelerates when pH exceeds 7.5 at temperatures above 30 °C. Acidic conditions below pH 2.0 are also unsuitable because the lactose carrier can hydrolyze, generating reducing sugars that interact with the benzimidazole amine functionality.

Packaging in cold-form aluminum foil with desiccant is required when storage humidity exceeds 60% RH; at 40 °C/75% RH open-package exposure for 7 days increases ivermectin degradation products by 0.8% and causes lactose carrier cakes to form. Manufacturing facilities in tropical climates should maintain suite relative humidity below 50% during dispensing and blending, because the lactose carrier undergoes deliquescence at approximately 70% RH at 25 °C, producing dark specks in compressed tablets. Dry heat sterilization is not recommended: ivermectin melts with decomposition near 155 °C, and albendazole shows thermodegradation above 180 °C, limiting hot-melt granulation processes to thermal loads below 60 °C. Processors should also avoid contact with strong oxidizing agents, which convert ivermectin to the corresponding N-oxide and can form sulfoxide derivatives of albendazole under high-shear blending.

Regulatory Quality Specifications and Pharmacopoeial Limits

In comparison with separate albendazole and ivermectin API powders, the fixed-ratio premix reduces the number of weighments on the dispensing floor from two to one for a single combination product, but it removes the ability to adjust each drug independently for species-specific parasitic spectra. The following operational distinctions are observed on production lines.

Cleaning validation for shared equipment must address two APIs with different solubility profiles. Albendazole is soluble in glacial acetic acid but poorly soluble in water; ivermectin is soluble in ethanol and dichloromethane. Swab recovery studies using stainless steel coupons should include an alkaline detergent wash followed by 70% v/v ethanol rinse. A total organic carbon limit of 10 ppm is insufficient for this low-dose combination; HPLC-based residue limits for ivermectin are typically set at 0.1 µg/cm² to prevent cross-contamination into non-target animal feeds. This limit is below the visible residue threshold because ivermectin is active at microgram per kilogram doses in some species, and carryover into equine or ivermectin-sensitive breed feeds may create a safety risk. Equipment used for final blending should be dedicated or validated through a worst-case product changeover study that includes swab sampling from blender discharge gates, vacuum transfer lines, and compression hopper walls after cleaning.